Stock exchange news | Navamedic

Read the latest news directly from the market.

Navamedic ASA acquires innovative antibiotic product for hospital use in the Nordic region

Clindamycin is a well-established antibiotic used in treatment of severe infections, including staphylococcal bone and joint infections, chronic sinusitis and Read more

Navamedic ASA: Q3 2022 financial results

“Looking back at another successful quarter, I am pleased to see that our strategic efforts to strengthen the existing business Read more

Navamedic ASA: Invitation to 2022 third quarter presentation

Oslo, October 25, 2022 - Navamedic ASA (OSE: Nava) will be presenting its third quarter 2022 results on Tuesday November Read more

Navamedic ASA launches ForlaxGO® – an innovative on-the-go product for the treatment of constipation

“Following the long-term agreement with Ipsen and the subsequent launch of SmectaGO® in February, we are pleased to announce the Read more

Navamedic ASA: Q2 and first half 2022 financial results

“We are pleased to report record-high revenues and continued strengthening of our profits and cash flow in the second quarter. Read more

Navamedic ASA: Invitation to 2022 second quarter presentation

Oslo, August 9, 2022 - Navamedic ASA (OSE: Nava) will be presenting its second quarter 2022 results on Friday, August Read more

Navamedic ASA – Exclusive agreement with Vectans Pharma for the unique cold sore treatment product Sitavig®

Oslo, 4 August 2022 - Navamedic has signed an agreement with the French pharmaceutical company Vectans Pharma, which gives Read more

Navamedic ASA: Trading Update

As the company’s preliminary consolidated financial results for the second quarter of 2022 (and hence first half of the year) Read more

Subscribe to stock exhange news